Pluri (PLUR) Restructuring Costs (2023 - 2024)
Pluri's (PLUR) quarterly Restructuring Costs came in at -$3000.0 in Q2 2024, down 101.16% year-over-year from $258000.0 in Q3 2023, and down 130.0% quarter-over-quarter from $10000.0 in Q1 2024.
Powered by 
Analysis
Pluri (PLUR) Restructuring Costs (2023 - 2024) Analysis & Trends
Pluri (PLUR) has reported Restructuring Costs for 2 consecutive years, with -$3000.0 the latest figure, recorded in Q2 2024.
- On a quarterly basis, Restructuring Costs fell 101.16% year-over-year to -$3000.0 in Q2 2024; TTM through Jun 2024 was $359000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $2000.0, down 99.09% from the prior year.
- Restructuring Costs was -$3000.0 for Q2 2024 at Pluri, down from $10000.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $310000.0 in Q1 2023 and troughed at -$3000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Pluri | 11.95 Mn | -536,034.04 | 86,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 94,000.00 |
| Jun 30, 2023 | 258,000.00 |
| Mar 31, 2023 | 310,000.00 |